Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;61(5):637-653.
doi: 10.1007/s40262-022-01116-3. Epub 2022 Mar 31.

Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review

Fleur M Keij  1   2 , Gerdien A Tramper-Stranders  3   4 , Birgit C P Koch  5 , Irwin K M Reiss  3 , Anouk E Muller  6   7 , René F Kornelisse  3 , Karel Allegaert  5   8   9
Affiliations

Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review

Fleur M Keij et al. Clin Pharmacokinet. 2022 May.

Abstract

Background and objective: Clavulanic acid is a commonly used β-lactam inhibitor in pediatrics for a variety of infections. Clear insight into its mode of action is lacking, however, and a target has not been identified. The dosing of clavulanic acid is currently based on that of the partner drug (amoxicillin or ticarcillin). Still, proper dosing of the compound is needed because clavulanic acid has been associated with adverse effects. In this systematic review, we aim to describe the current literature on the pharmacokinetics of clavulanic acid in the pediatric population METHODS: We performed a systematic search in MEDLINE, Embase.com, Cochrane Central, Google Scholar, and Web of Science. We included all published studies reporting pharmacokinetic data on clavulanic acid in neonates and children 0-18 years of age.

Results: The search resulted in 18 original studies that met the inclusion criteria. In general, the variation in drug exposure was large, which can be partly explained by differences in disease state, route of administration, or age. Unfortunately, the studies' limited background information hampered in-depth assessment of the observed variability.

Conclusion: The pharmacokinetics of clavulanic acid in pediatric patients is highly variable, similar to reports in adults, but more pronounced. Significant knowledge gaps remain with regard to the population-specific explanation for this variability. Model-based pharmacokinetic studies that address both maturational and disease-specific changes in the pediatric population are therefore needed. Furthermore, additional pharmacodynamic studies are needed to define a clear target. The combined outcomes will eventually lead to pharmacokinetic-pharmacodynamic modeling of clavulanic acid and targeted exposure.

Clinical trial registration: PROSPERO CRD42020137253.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Flowchart of the inclusion process. PK pharmacokinetics
Fig. 2
Fig. 2
Publications on the pharmacokinetics (PK) of clavulanic acid in pediatrics in time
Fig. 3
Fig. 3
a Serum concentrations, corrected for dose, in time following oral clavulanic acid administration. b Serum concentrations, corrected for dose, in time following intravenous clavulanic acid administration. LBWI: low birth weight infants
See this image and copyright information in PMC

References

    1. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the sustainable development goals. Lancet. 2016;388(10063):3027–3035. doi: 10.1016/s0140-6736(16)31593-8. - DOI - PMC - PubMed
    1. Jackson C, Hsia Y, Bielicki JA, Ellis S, Stephens P, Wong ICK, et al. Estimating global trends in total and childhood antibiotic consumption, 2011–2015. BMJ Glob Health. 2019;4(1):e001241. doi: 10.1136/bmjgh-2018-001241. - DOI - PMC - PubMed
    1. Schuller SS, Kramer BW, Villamor E, Spittler A, Berger A, Levy O. Immunomodulation to prevent or treat neonatal sepsis: past, present, and future. Front Pediatr. 2018;6:199. doi: 10.3389/fped.2018.00199. - DOI - PMC - PubMed
    1. Medernach RL, Logan LK. The growing threat of antibiotic resistance in children. Infect Dis Clin N Am. 2018;32(1):1–17. doi: 10.1016/j.idc.2017.11.001. - DOI - PMC - PubMed
    1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10:226–236.

Publication types